Goldman Sachs Maintains Buy on Sarepta Therapeutics, Raises Price Target to $215
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Salveen Richter maintains a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) and raises the price target from $188 to $215.
June 23, 2023 | 2:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs maintains a Buy rating on Sarepta Therapeutics and raises the price target from $188 to $215.
Goldman Sachs' Buy rating and increased price target for Sarepta Therapeutics indicate a positive outlook for the company's stock. This news is likely to have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100